An in vivo assessment in 2 xenograft tumor models over-expressing HER2, BT-474 and NCI-N87, was used to demonstrate that, like trastuzumab, ABP 980 has the ability to inhibit tumor growth in both breast and gastric cancer tumors in an in vivo setting. This evidence concerns the gene ERBB2 and neoplasm.